Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 5/20 | 0.48 |
| ▸ | RXRA | P19793 | 4/20 | 0.48 |
| ▸ | RXRG | P48443 | 3/20 | 0.48 |
| ▸ | CD44 | P16070 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13190494 | 0.85 | CD44 (0.49) | RXRBRXRARXRGCD44CFD | |
| SCHEMBL2857359 | 0.83 | HTR6 (0.52) | RXRBRXRACD44CFDF11 | |
| SCHEMBL17583876 | 0.83 | CHRM2 (0.45) | CD44CFDF11CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL3798819 | 0.82 | HTR6 (0.51) | RXRBRXRACD44CFDF11 | |
| SCHEMBL30973516 | 0.81 | RXRB (0.58) | RXRBRXRARXRGHTR1AMAPT | |
| SCHEMBL22632798 | 0.81 | RXRB (0.58) | RXRBRXRARXRGHTR1AMAPT | |
| SCHEMBL8185445 | 0.80 | CD44 (0.51) | CD44HTR2CHTR2BHTR2A | |
| SCHEMBL17583878 | 0.80 | ACACB (0.44) | CFDF11CHRM2CHRM4CHRM5 | |
| Acetonitrile SCHEMBL9303867 | 0.79 | MAPT (0.46) | RXRBRXRARXRGHTR1ASLC6A2 | |
| Ammonia Solution, Strong SCHEMBL8189446 | 0.79 | CD44 (0.50) | CD44HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7375099-B2 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1592684-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| EP-0873317-B1 | PYRIMIDIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | EP | disclosed |
| CN-1199397-A | Pyrimidin derivatives | HOFFMANN LA ROCHE (CH) | 1998-11-18 | — | — | CN | disclosed |
| EP-0873317-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| US-5688798-A | PSYCHOTIC ILLNESS SUCH AS SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997013759-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | RXRB 4289/4885RXRA 4250/4885RXRG 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.